-
srdr.ahrq.gov/projects/1671/studies/196129
January 01, 2019 - What is the comparative effectiveness of nonopioid pharmacologic therapy (e.g. acetaminophen, NSAIDs, … , combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) other nonopioid … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … (e.g. age, race, ethnicity, gender); (2) patient medical comorbidities; (3) the type of nonopioid medication … What are the harms of nonopioid pharmacologic therapy versus other nonopioid pharmacologic therapy, or
-
srdr.ahrq.gov/projects/1671/studies/196132
January 01, 2018 - What is the comparative effectiveness of nonopioid pharmacologic therapy (e.g. acetaminophen, NSAIDs, … , combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) other nonopioid … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … (e.g. age, race, ethnicity, gender); (2) patient medical comorbidities; (3) the type of nonopioid medication … What are the harms of nonopioid pharmacologic therapy versus other nonopioid pharmacologic therapy, or
-
srdr.ahrq.gov/projects/1671/studies/196111
January 01, 2019 - What is the comparative effectiveness of nonopioid pharmacologic therapy (e.g. acetaminophen, NSAIDs, … , combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) other nonopioid … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … (e.g. age, race, ethnicity, gender); (2) patient medical comorbidities; (3) the type of nonopioid medication … What are the harms of nonopioid pharmacologic therapy versus other nonopioid pharmacologic therapy, or
-
srdr.ahrq.gov/projects/1671/studies/196119
January 01, 2019 - What is the comparative effectiveness of nonopioid pharmacologic therapy (e.g. acetaminophen, NSAIDs, … , combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) other nonopioid … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … (e.g. age, race, ethnicity, gender); (2) patient medical comorbidities; (3) the type of nonopioid medication … What are the harms of nonopioid pharmacologic therapy versus other nonopioid pharmacologic therapy, or
-
srdr.ahrq.gov/projects/1671/studies/196182
January 01, 2019 - What is the comparative effectiveness of nonopioid pharmacologic therapy (e.g. acetaminophen, NSAIDs, … , combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) other nonopioid … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … (e.g. age, race, ethnicity, gender); (2) patient medical comorbidities; (3) the type of nonopioid medication … What are the harms of nonopioid pharmacologic therapy versus other nonopioid pharmacologic therapy, or
-
srdr.ahrq.gov/projects/1671/studies/196168
January 01, 2019 - What is the comparative effectiveness of nonopioid pharmacologic therapy (e.g. acetaminophen, NSAIDs, … , combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) other nonopioid … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … (e.g. age, race, ethnicity, gender); (2) patient medical comorbidities; (3) the type of nonopioid medication … What are the harms of nonopioid pharmacologic therapy versus other nonopioid pharmacologic therapy, or
-
srdr.ahrq.gov/projects/1671/studies/196176
What is the comparative effectiveness of nonopioid pharmacologic therapy (e.g. acetaminophen, NSAIDs, … , combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) other nonopioid … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … (e.g. age, race, ethnicity, gender); (2) patient medical comorbidities; (3) the type of nonopioid medication … What are the harms of nonopioid pharmacologic therapy versus other nonopioid pharmacologic therapy, or
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f1-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
September 20, 2022 - NPP_Pain
Table F-1a. Pain severity for neuropathic pain
Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug 1 Drug 2 Measure Name Measure Scale Assessment Time (Wk) Time Category Grp 1 Baseline N Grp 1 Baseline Mean Pain Score Grp1 Baseline Variance Type Grp1 Baseline Variance Grp1 Baseline Lower Limi…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-g-surv-report-2-nonopioid-pharmacol-chronic-pain.xlsx
September 20, 2022 - RCTs
Table G-1. Quality assessments of included randomized controlled trials
Author, Year Randomization Adequate Allocation Concealment Adequate Patients and Personnel Masked Outcome Assessors Masked Groups Similar at Baseline Intent-to-Treat Analysis (at Least 95% Analyzed) Attrition <20%; Difference Between Groups …
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-g-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
September 20, 2022 - RCTs
Table G-1. Quality assessments of included randomized controlled trials
Author, Year Randomization Adequate Allocation Concealment Adequate Patients and Personnel Masked Outcome Assessors Masked Groups Similar at Baseline Intent-to-Treat Analysis (at Least 95% Analyzed) Attrition <20%; Difference Between Groups …
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f2-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
September 20, 2022 - TCA_PCT
Table F-2a. Harms of tricyclic antidepressants versus placebo
Author, Year Quality Pain Population Drug Class Drug Assessment Time (Wk) Time Category WAE: n WAE: N SAE: n SAE: N Cardiac Rhythm Abnormalities: Specific AE Cardiac Rhythm Abnormalities: n Cardiac Rhythm Abnormalities: N N Randomized Cognitive Eff…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-g-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
September 20, 2022 - RCTs
Table G-1. Quality assessments of included randomized controlled trials
Author, Year Randomization Adequate Allocation Concealment Adequate Patients and Personnel Masked Outcome Assessors Masked Groups Similar at Baseline Intent-to-Treat Analysis (at Least 95% Analyzed) Attrition <20%; Difference Between Groups …
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f2-surv-report-2-nonopioid-pharmacol-chronic-pain.xlsx
September 20, 2022 - TCA_PCT
Table F-2a. Harms of tricyclic antidepressants versus placebo
Author, Year Quality Pain Population Drug Class Drug Assessment Time (Wk) Time Category WAE: n WAE: N SAE: n SAE: N Cardiac Rhythm Abnormalities: Specific AE Cardiac Rhythm Abnormalities: n Cardiac Rhythm Abnormalities: N N Randomized Cognitive Eff…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f1-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
September 20, 2022 - NPP_Pain
Table F-1a. Pain severity for neuropathic pain
Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug 1 Drug 2 Measure Name Measure Scale Assessment Time (Wk) Time Category Grp 1 Baseline N Grp 1 Baseline Mean Pain Score Grp1 Baseline Variance Type Grp1 Baseline Variance Grp1 Baseline Lower Limi…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
September 20, 2022 - NPP
Table E-1. Neuropathic pain study characteristics
Author, Year
Country
Trial Type
Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized
N Analyzed Intervention Duration (Weeks) Funding Source
Hussain, 2021
Pakistan
Placebo-controlled
Fair NPP (DPN) Age, mean: 45
Female: 0%
R…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
September 20, 2022 - NPP
Table E-1. Neuropathic pain study characteristics
Author, Year
Country
Trial Type
Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized
N Analyzed Intervention Duration (Weeks) Funding Source
Hussain, 2021
Pakistan
Placebo-controlled
Fair NPP (DPN) Age, mean: 45
Female: 0%
R…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f1-surv-report-2-nonopioid-pharmacol-chronic-pain.xlsx
September 20, 2022 - NPP_Pain
Table F-1a. Pain severity for neuropathic pain
Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug 1 Drug 2 Measure Name Measure Scale Assessment Time (Wk) Time Category Grp 1 Baseline N Grp 1 Baseline Mean Pain Score Grp1 Baseline Variance Type Grp1 Baseline Variance Grp1 Baseline Lower Limi…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-2-nonopioid-pharmacol-chronic-pain.xlsx
September 20, 2022 - NPP
Table E-1. Neuropathic pain study characteristics
Author, Year
Country
Trial Type
Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized
N Analyzed Intervention Duration (Weeks) Funding Source
Hussain, 2021
Pakistan
Placebo-controlled
Fair NPP (DPN) Age, mean: 45
Female: 0%
R…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f2-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
September 20, 2022 - TCA_PCT
Table F-2a. Harms of tricyclic antidepressants versus placebo
Author, Year Quality Pain Population Drug Class Drug Assessment Time (Wk) Time Category WAE: n WAE: N SAE: n SAE: N Cardiac Rhythm Abnormalities: Specific AE Cardiac Rhythm Abnormalities: n Cardiac Rhythm Abnormalities: N N Randomized Cognitive Eff…
-
srdr.ahrq.gov/projects/1671/studies/196180
What is the comparative effectiveness of nonopioid pharmacologic therapy (e.g. acetaminophen, NSAIDs, … , combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) other nonopioid … How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics … (e.g. age, race, ethnicity, gender); (2) patient medical comorbidities; (3) the type of nonopioid medication … What are the harms of nonopioid pharmacologic therapy versus other nonopioid pharmacologic therapy, or